$RMTI

Rockwell Medical (RMTI) reported Q2 2026 net sales of $17.8 million, up 11% year over year, with gross profit $3.2 million and gross margin expanding to 18%. Net loss improved to $1.2 million, and operating cash flow turned positive at $2.1 million. FY 2026 guidance: revenue $70 million to $75 million, gross margin 18% to 22%, and adjusted EBITDA $1 million to $2 million. The company completed a 1-for-10 reverse split for Nasdaq bid-price compliance.

Rockwell Medical, Inc. reported Q2 2026 progress on gross margin expansion, attributing it to improved operating efficiency and activation of two automated liquid production lines. Management said it is shifting to longer-term customer agreements, targeting ~30% gross margin and $100M+ annual net sales by 2029. Operating cash flow returned to $2.1M, including Evoqua acquisition payments.

ROCKWELL MEDICAL, INC. (RMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2-26xearningsxpr.htm EX-99.1 Document Rockwell Medical Announces Second Quarter 2026 Results • Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025 • Gross

ROCKWELL MEDICAL, INC. (RMTI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rmti-20260612 0001041024 FALSE 0001041024 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Rockwell Medical (NASDAQ: RMTI) has renewed and extended its product purchase agreement with aQua Dialysis, LLP for two years with options for additional one-year periods. This agreement secures Rockwell Medical's continued supply of hemodialysis concentrates and related products to aQua Dialysis. The company, which recently reported mixed Q1 2026 earnings and received a Nasdaq non-compliance notice, is working to secure strategic partnerships and improve its financial standing.

Rockwell Medical, Inc. (RMTI) received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days, placing it at risk of delisting. The company has 180 calendar days, until November 4, 2026, to regain compliance by having its closing bid price at or above $1.00 for ten consecutive business days. Rockwell Medical plans to propose a reverse stock split in its 2026 proxy statement as a potential solution.

Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rockwell Medical (RMTI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Rockwell Medical (RMTI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Image source: The Motley Fool.Thursday, August 14, 2025 at 8 a.m. ETPresident and Chief Executive Officer - Mark StrobeckContinue reading ...